Nonapeptide-1: cosmetic use and the state of research
Clinical review pending
Nonapeptide-1 is claimed to affect pigment production. What lab studies show, and what evidence of an effect on the skin's appearance is missing.
What is nonapeptide-1?
Nonapeptide-1 is a synthetic peptide made of nine amino acids. In skincare products it is sold under the name Melanostatine, for example Melanostatine-5. It is meant to make dark spots and uneven skin tone less visible without bleaching the skin. It is a cosmetic ingredient, not a drug. Source
How does it work?
Lab studies describe nonapeptide-1 as an inhibitor of one particular signal for pigment production. Melanocytes, the skin’s pigment-producing cells, make more melanin when the hormone alpha-MSH binds to MC1R, a receptor on their surface. Nonapeptide-1 is thought to compete with alpha-MSH for this binding site. That weakens the downstream signal that switches on melanin-producing enzymes. In cell studies 1 it was used as a reference antagonist that reduces melanin production.
The idea is aimed more at prevention than at correcting existing spots: a weaker signal for making new pigment is supposed to limit the formation of further dark spots rather than remove pigment already there. These are lab findings. For finished cosmetic products, the intended benefit is described as a change in appearance, such as a brighter, more even-looking complexion.
Is the ingredient FDA approved?
No. For the cosmetic use described here, no such drug approval is required. The FDA does not approve cosmetic ingredients in advance. A cosmetic may describe effects on how skin tone looks; a claim to treat a pigmentation disorder, by contrast, would classify the product as a drug. Nonapeptide-1 is used to change the skin’s appearance cosmetically.
What is it used for?
Nonapeptide-1 appears in brightening serums and creams meant to make dark spots, hyperpigmentation and uneven skin tone less visible. It is often combined with other ingredients such as niacinamide or vitamin C. Because UV radiation drives pigment production, daily sun protection is usually part of using it in practice. Source
What does the research show?
The evidence is thin and comes mostly from lab work. In a cell study indexed on PubMed 1, nonapeptide-1 was used for comparison as a known alpha-MSH inhibitor. This supports its pigment-inhibiting activity in the lab. The manufacturer reports a brightening effect on the skin; however, the source article found no corresponding independent, peer-reviewed human study of the ingredient on its own. The proposed mechanism is therefore supported by lab research, not by published human studies on skin appearance.
What side effects are known?
At the concentrations usual in cosmetics, nonapeptide-1 is mostly described as well tolerated and non-irritating. It is marketed as a gentler alternative to some older brightening ingredients. Independent human safety data are limited, though. For sensitive skin it may therefore make sense to try a patch test on a small area first.
References provided in the source article
Sources: a cell study using nonapeptide-1 as an alpha-MSH antagonist reference (Chen et al., Advances in Dermatology and Allergology, 2022, DOI: 10.5114/ada.2022.115890 1 ), indexed on PubMed; and manufacturer and cosmetic ingredient reference data on Melanostatine.
Provenance and editorial review status
Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.